Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KTTA
- Price
- 0.75
- Stock movement up
- +0.01 (1.01%)
- Company name
- Pasithea Therapeutics Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.30M
- Ent value
- 819.91M
- Price/Sales
- 5.43
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -3.13%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -84.71%
- 3 year return
- -69.86%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KTTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.43 |
| Price to Book | - |
| EV to Sales | 839.81 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 7.44M |
| EPS (TTM) | -2885.24 |
| FCF per share (TTM) | -10998.21 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 976.31K |
| Gross profit (TTM) | 489.57K |
| Operating income (TTM) | -16.14M |
| Net income (TTM) | -3.01B |
| EPS (TTM) | -2.89K |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 50.15% |
| Operating margin (TTM) | -1653.09% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.36M |
| Net receivables | 0.00 |
| Total current assets | 9.78B |
| Goodwill | 1.26M |
| Intangible assets | 7.47M |
| Property, plant and equipment | 0.00 |
| Total assets | 18.64M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 660.40M |
| Total liabilities | 823.98M |
| Shareholder's equity | -805.34M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.48B |
| Capital expenditures (TTM) | 36.00 |
| Free cash flow (TTM) | -11.48B |
| Dividends paid (TTM) | 359.66M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -16164.29% |
| Return on Invested Capital | 374.08% |
| Cash Return on Invested Capital | 1425.95% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.71 |
| Daily high | 0.72 |
| Daily low | 0.69 |
| Daily Volume | 35K |
| All-time high | 112.00 |
| 1y analyst estimate | 2.00 |
| Beta | 0.26 |
| EPS (TTM) | -2885.24 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KTTA | S&P500 | |
| Current price drop from All-time high | -99.36% | -1.46% |
| Highest price drop | -99.39% | -56.47% |
| Date of highest drop | 11 Aug 2025 | 9 Mar 2009 |
| Avg drop from high | -86.04% | -10.99% |
| Avg time to new high | 329 days | 12 days |
| Max time to new high | 938 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.30M
Marketcap category
Small-cap
Description
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner